STOCK TITAN

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Soligenix, a late-stage biopharmaceutical company, has made significant advancements in its product pipeline, with its lead clinical asset, HyBryte™ or SGX301, showing positive results in a Phase 3 study. The company is also progressing with SGX302 for psoriasis and SGX203 for pediatric Crohn's disease. Additionally, Soligenix has achieved milestones in public health solutions, including promising data from its filovirus vaccine program. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite, global footprint, and recent milestones in defense deals. The company is financially robust and poised to shift its revenue focus from hardware to Software-as-a-Service (SaaS) and recurring cybersecurity revenues from 2024.
Positive
  • None.
Negative
  • None.

The recent updates from Soligenix, Inc. and Mobilicom Limited highlight significant developments that could influence their respective markets and investor perspectives. Soligenix's advancement in its clinical pipeline, especially the move towards a second Phase 3 study for its lead asset HyBryte™, indicates a steady progression towards market entry. With a targeted market potential of $250 million for CTCL treatments, the successful commercialization of HyBryte™ could capture a substantial market share given the unmet medical needs in this space.

Furthermore, the combined commercial prospects of approximately $2 billion for Soligenix's products in development for psoriasis and pediatric Crohn's disease represent a significant growth opportunity. The potential receipt of Priority Review Vouchers for their public health solutions, including their filovirus vaccine program, could expedite the regulatory review process and enhance the company's value proposition.

Mobilicom's recent corporate update showcases a robust financial position with a 62% gross margin and a strong cash balance of $10.6 million, which is commendable for a company in the technology sector. The absence of bank debt and a low burn rate are indicators of prudent financial management. The company's pivot towards a Software-as-a-Service (SaaS) model could lead to more stable and predictable recurring revenue streams, aligning with current industry trends favoring software over hardware revenues.

The $900,000 order from a top-tier Israeli defense manufacturer and a significant U.S. defense deal are testaments to the company's growing market presence and the relevance of its proprietary technology suite in the defense sector. The move to SaaS and cybersecurity services could potentially expand profit margins and enhance long-term shareholder value.

Mobilicom's suite of products, including SkyHopper Datalinks and the ICE Cybersecurity Suite, positions the company at the forefront of the drone and robotics technology space, which is increasingly critical for both civilian and defense applications. The mention of 50 'design wins' signifies the company's competitive edge and adoption of its technology in integrated solutions. The emphasis on cybersecurity and cloud management also aligns with the growing need for secure communication systems in defense and commercial drone operations.

The strategic shift to SaaS models could enhance Mobilicom's adaptability and scalability in the fast-evolving drone technology market. Their global footprint and intellectual property portfolio reinforce their market position and could attract strategic partnerships or acquisitions, especially from larger defense contractors seeking to expand their unmanned systems capabilities.

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

In an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Soligenix, a late-stage biopharmaceutical company, has announced significant advancements in its product pipeline, which focuses on treatments that address unmet medical needs. Its lead clinical asset, HyBryte™ or SGX301, a therapy for cutaneous T-cell lymphoma (CTCL), has shown positive results in a Phase 3 study and is expected to enter a second confirmatory Phase 3 study following FDA discussions, targeting a market potential of $250 million. The company is also progressing with SGX302 for psoriasis, currently in Phase 2a trials, and SGX203 for pediatric Crohn's disease, anticipating a pivotal Phase 3 study. These products have combined commercial prospects of approximately $2 billion. Additionally, Soligenix has achieved milestones in public health solutions, including promising data from its filovirus vaccine program, demonstrating protection against Sudan ebolavirus and Marburg virus, supported by NIH grants and potential Priority Review Vouchers. This diverse portfolio positions Soligenix strongly in areas of significant commercial and medical interest.

Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Recent milestones include a $900,000 order from a top-tier Israeli defense manufacturer and a significant U.S. defense deal. Financially robust, Mobilicom reported a 62% gross margin in 2022, a strong cash balance of $10.6 million as of June 30, 2023, no bank debt, and a low burn rate. The company is poised to shift its revenue focus from hardware to Software-as-a-Service (SaaS) and recurring cybersecurity revenues from 2024. These factors, combined with its innovative solutions, expanding customer base, and significant market potential, make Mobilicom an attractive investment proposition in the burgeoning drone and robotics market.

About Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease. The Company also is developing proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation such as pediatric Crohn's disease (SGX203).

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg, Sudan and Ebola) and CiVax, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

About Mobilicom

Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.

For investors, please use https://ir.mobilicom.com/
For company, please use www.mobilicom.com

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com

SOURCE: RedChip



View the original press release on accesswire.com

FAQ

What is the ticker symbol for Soligenix, Inc.?

The ticker symbol for Soligenix, Inc. is SNGX.

What are the products in Soligenix's product pipeline?

Soligenix's product pipeline includes HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, and SGX203 for pediatric Crohn's disease.

What advancements has Soligenix made in its product pipeline?

Soligenix has made significant advancements in its product pipeline, with HyBryte™ (SGX301) showing positive results in a Phase 3 study and progressing with SGX302 for psoriasis and SGX203 for pediatric Crohn's disease.

What milestones has Soligenix achieved in public health solutions?

Soligenix has achieved promising data from its filovirus vaccine program, demonstrating protection against Sudan ebolavirus and Marburg virus, supported by NIH grants and potential Priority Review Vouchers.

What is the ticker symbol for Mobilicom Limited?

The ticker symbol for Mobilicom Limited is MOB.

What are the recent milestones for Mobilicom?

Mobilicom's recent milestones include a $900,000 order from a top-tier Israeli defense manufacturer and a significant U.S. defense deal.

What is Mobilicom's revenue focus shifting to from 2024?

Mobilicom is poised to shift its revenue focus from hardware to Software-as-a-Service (SaaS) and recurring cybersecurity revenues from 2024.

Soligenix, Inc.

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Stock Data

5.94M
10.48M
0.1%
3.66%
1.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About SNGX

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.